Dabigatran is an anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications, for some of which it may replace warfarin as the preferred anticoagulant. It is orally administered as the prodrug dabigatran etexilate (marketed as Pradaxa since April in European countries and Pradax in Canada). It was developed by pharmaceutical company Boehringer-Ingelheim.
5 edits since May 19, 2008. Last edited Jul 20, 2008 by Carlo Banez (49).
This Compound Monograph is licensed under the GNU Free Documentation License and uses material from the Wikipedia article Dabigatran. See this site's terms for details.